This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Discussing the results from the CheckMate-901 trial of the Opdivo (nivolumab), cisplatin, and gemcitabine combo for urothelial carcinoma
Ticker(s): BMYWho's the expert?
Institution: Odette Cancer Centre
- Medical Oncologist and assistant professor of medicine at the University of Toronto
- Manages 100 patients with bladder cancer
-
Research Focus in Health care services research and Neuroendocrine head and neck malignancies
Interview GoalThis interview will focus on the recent news of the FDA approved nivolumab, marketed as Opdivo, to be administered in combination with the chemotherapies cisplatin and gemcitabine to treat adults with unresectable or metastatic urothelial carcinoma. The approval was based on positive results from BMS’ CheckMate-901 trial, which evaluated overall survival and progression-free survival in about 600 patients who had not previously received treatment.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
